Literature DB >> 31058360

Similarities and differences in the correlates of comorbidities in US male and female adult cancer survivors.

So-Hyun Park1, Shiela M Strauss1,2.   

Abstract

OBJECTIVES: To determine both the common and the sex-specific correlates of comorbidities in adult male and female cancer survivors.
DESIGN: Cross-sectional study using the 2009-2014 National Health and Nutrition Examination Survey (NHANES). SAMPLE: Male (n = 667) and female (n = 772) cancer survivors 20 years of age and older. MEASUREMENTS: Questionnaire responses from NHANES provided data for this study. Comorbidities were assessed using a modified Charlson Comorbidity Index (CCI). Bivariate and multivariate linear regression analyses were conducted to identify correlates of comorbidities in male and female cancer survivors separately.
RESULTS: The mean modified CCI score was 3.88 in males and 3.68 in females. Having a greater number of cancers diagnosed, being currently or formerly married, being physically inactive, having lower socioeconomic status, and being a former smoker were significant correlates of comorbidities in both males and females. Having a prostate cancer diagnosis was also a significant correlate of comorbidities in males. White race, more years since first cancer diagnosis, being overweight or obese, and having no more than a high school education were also significant correlates of comorbidities in females.
CONCLUSIONS: There are differences between correlates of comorbidities in male and female cancer survivors.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer survivors; comorbidity; survivorship

Mesh:

Year:  2019        PMID: 31058360     DOI: 10.1111/phn.12617

Source DB:  PubMed          Journal:  Public Health Nurs        ISSN: 0737-1209            Impact factor:   1.462


  1 in total

1.  Multimorbidity and Employment Outcomes Among Middle-Aged US Cancer Survivors.

Authors:  Christine C Ekenga; BoRin Kim; Eunsun Kwon; Sojung Park
Journal:  J Occup Environ Med       Date:  2022-06-01       Impact factor: 2.306

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.